Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2018 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea gibt Halbjahresergebnisse bekannt, geprägt von starkem Wachstum der In-Market-Sales ihrer Produkte sowie vom Fortschritt und der Erweiterung ihrer F&E-Pipeline

Gesamtumsatz um 30 % auf CHF 59.9 Mio. gesteigert, Ausblick für Gesamtumsatz 2018 auf CHF 120 - 130 Mio. erhöht Lizenzgebühren (Royalties) auf Cresemba-Umsätze auf CHF 10.8 Mio. mehr als...
August 14, 2018 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline

Total revenue increased by 30% to CHF 59.9 million; 2018 total revenue guidance is increased to CHF 120 - 130 million Royalties on Cresemba sales more than doubled to CHF 10.8 million Clinical...
August 13, 2018 08:00 ET | Source: CUV Ventures Corp.

CUV Ventures Corp. RevoluCHARGE DA Signed With CY Talk Geneva Switzerland

VANCOUVER, British Columbia, Aug. 13, 2018 (GLOBE NEWSWIRE) -- CUV Ventures Corp. (TSX-V: CUV) (the “Company”) is pleased to announce that the wholly owned subsidiary, RevoluPAY® S.L, has entered...
August 13, 2018 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea berichtet über erste Cresemba®-Zulassung in der MENA-Region

Basel, 13. August 2018 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Hikma Pharmaceuticals LLC die Zulassung für das Antimykotikum Cresemba® (Isavuconazol) in Jordanien...
August 13, 2018 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea reports on first Cresemba® approval in MENA region

Basel, Switzerland, August 13, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Hikma Pharmaceuticals LLC, gained regulatory approval for the antifungal Cresemba®...
August 09, 2018 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea startet klinische Phase-3-Studie mit Antibiotikum Ceftobiprol bei Staphylococcus-aureus-Bakteriämie (SAB)

Basel, 09. August 2018 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute den Beginn einer Phase-3-Studie mit ihrem Antibiotikum Ceftobiprol bekannt. In der zulassungsrelevanten Studie wird die...
August 09, 2018 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)

Basel, Switzerland, August 09, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 3 study with its antibiotic ceftobiprole. The registration study evaluates...
August 08, 2018 08:00 ET | Source: CUV Ventures Corp.

CUV Ventures Corp. Level 5 Research Releases initial Corporate Overview on CUV Ventures Corp.

VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- CUV Ventures Corp. (TSX-V:CUV) (the “Company”) is pleased to announce that Level 5 Research, a Fact-based corporate research group,...
August 07, 2018 08:00 ET | Source: CUV Ventures Corp.

CUV Ventures Corp. Constellation Software Inc. Subsidiary Juniper Contracted For RevoluVIP Travel Club XML GDS Technology

VANCOUVER, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- CUV Ventures Corp. (TSX-V: CUV) (the “Company”) Vancouver, BC – (the “Company”) is pleased to announce that the wholly owned Travel...
July 31, 2018 08:00 ET | Source: CUV Ventures Corp.

CUV Ventures Corp. RevoluPAY® App launched on Google Play and Android Platforms

VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) -- CUV Ventures Corp. (TSX-V: CUV) (the “Company”) Vancouver, BC – (the “Company”) is pleased to announce that the RevoluPAY® app has been...